DelveInsight’s “Chronic Gout Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Gout, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Chronic Gout Market with DelveInsight’s In-Depth Report @ https://www.delveinsight.com/sample-request/chronic-gout-market
Key Takeaways from the Chronic Gout Market Report
- According to secondary research, the prevalence of gout among US adults is 3.9%, with a higher burden in men at 5.2% and in women at 2.7%.
- As per the secondary analysis, approximately 13% of patients with gout had chronic gout marked by uncontrolled serum urate levels and persistent clinical manifestations.
- In Germany, the prevalence of gout among adults is estimated to be between 1–2%.
- As per available data, the prevalence of gout in the adult population of France was around 0.9 percent.
- According to the secondary research, the prevalence of gout in the UK was around 2.49 percent.
- In Japan, the prevalence of gout was 1.1%, with a significantly higher rate in men at 1.9% and less than 0.1% in women.
- The leading Chronic Gout Companies such as Sobi, Cartesian Therapeutics, Arthrosi Therapeutics, Atom Therapeutics, and others.
- Promising Chronic Gout Therapies such as NASP (formerly SEL-212), Pozdeutinurad (AR882), Lingdolinurad (ABP-671), and others
Stay ahead in the Chronic Gout Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Gout Market Outlook
Chronic Gout Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases of Gout
- Type-specific Diagnosed Prevalent Cases of Gout
- Total Diagnosed Prevalent Cases of Chronic Gout
- Treated Cases of Chronic Gout
Download the report to understand which factors are driving Chronic Gout Epidemiology trends @ Chronic Gout Prevalence
Chronic Gout Marketed Drugs
- KRYSTEXXA (pegloticase): Amgen
KRYSTEXXA (pegloticase) is a PEGylated uric acid–specific enzyme administered via intravenous injection. It is indicated for the treatment of chronic gout in adult patients who are refractory to conventional therapies. By enzymatically converting uric acid to allantoin, a more soluble and easily excreted compound, KRYSTEXXA lowers serum urate levels in patients with uncontrolled gout who have not responded adequately to standard treatment options
Chronic Gout Emerging Drugs
- NASP (formerly SEL-212): Swedish Orphan Biovitrum (Sobi)/Cartesian Therapeutics
NASP (nanoencapsulated sirolimus plus pegadricase) is a novel, once-monthly investigational combination therapy for chronic refractory gout, designed to lower serum urate levels and help reduce tissue urate deposits that can lead to gout flares and joint deformities if untreated.
- Pozdeutinurad (AR882): Arthrosi Therapeutics
Pozdeutinurad (AR882) is a highly potent and selective next-generation urate transporter 1 (URAT1) inhibitor in development for the treatment of gout, targeting serum urate reduction, flare prevention, and tophi resolution. It is currently in Phase III for the chronic management of gout and in Phase II for refractory tophaceous gout. In Phase II studies, AR882 showed superior efficacy over standard-of-care therapies, with the 75 mg dose reducing serum urate to <4 mg/dL in 88% of patients—compared to none with allopurinol or febuxostat. It also demonstrated complete tophi resolution in a Phase IIb trial and a favorable safety profile.
Lingdolinurad (ABP-671): Atom Therapeutics
ABP-671 is a once-daily oral inhibitor of urate transporter 1 (URAT1) that reduces uric acid reabsorption in the kidneys, promoting urinary excretion and lowering serum uric acid (sUA) levels. Long-term use helps dissolve existing tophi, prevent gout flares, and reduce hyperuricemia-related complications such as cardiovascular, renal, and metabolic disorders. Clinical guidelines recommend maintaining sUA below 6 mg/dL to prevent new crystal formation and below 5 mg/dL to accelerate tophi resolution. In a Phase IIa trial, ABP-671 achieved these targets in 93% (<6 mg/dL) and 77% (<5 mg/dL) of patients, supporting its advancement to global Phase III trials and commercialization by Atom Therapeutics.
Chronic Gout Market Outlook
“Chronic gout is a metabolic disorder driven by sustained hyperuricemia, leading to monosodium urate crystal deposition in joints and soft tissues. This crystal-induced inflammation causes acute flares, persistent synovial and bony changes, tophi formation, erosive joint damage, and chronic pain if untreated. Its development and severity are influenced by genetic predisposition, diet, kidney function, and comorbidities such as hypertension and obesity, underscoring the interplay of metabolic and inflammatory factors.”
Get In-Depth Knowledge on Chronic Gout Market Trends and Forecasts with DelveInsight @ Chronic Gout Treatment Market
Chronic Gout Treatment Market
The current treatment options for chronic gout, including allopurinol, febuxostat, and probenecid, are available as generics, providing widely accessible and cost-effective options for long-term urate-lowering therapy. In contrast, KRYSTEXXA (pegloticase) is a branded, FDA-approved biologic indicated explicitly for adults with chronic gout that is refractory to conventional treatments. KRYSTEXXA is a PEGylated, uric acid–specific enzyme administered intravenously, which works by converting uric acid into allantoin, aa more soluble compound that is easily excreted, effectively reducing serum urate levels in patients whose gout remains uncontrolled despite standard therapy.
Chronic Gout Therapeutics Market
“In chronic gout, acute flares are managed with NSAIDs, colchicine, or corticosteroids to quickly reduce pain and inflammation. Long-term management focuses on maintaining serum urate below 6 mg/dL, or below 5 mg/dL in severe cases, typically with xanthine oxidase inhibitors, while uricosurics or uricase therapies are used for refractory or intolerant patients. Ongoing patient education, routine monitoring, and lifestyle adjustments help maintain control and prevent disease progression.”
Scope of the Chronic Gout Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Chronic Gout Companies- Sobi, Cartesian Therapeutics, Arthrosi Therapeutics, Atom Therapeutics, and others.
- Chronic Gout Therapies- NASP (formerly SEL-212), Pozdeutinurad (AR882), Lingdolinurad (ABP-671), and others
- Chronic Gout Therapeutic Assessment: Chronic Gout current marketed and Chronic Gout emerging therapies
- Chronic Gout Market Dynamics: Chronic Gout market drivers and Chronic Gout market barriers
- Chronic Gout Unmet Needs, KOL’s views, Analyst’s views, Chronic Gout Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Gout Market Report @ Chronic Gout Market Drivers and Barriers
Table of Content
1 Key Insights
2 Chronic Gout Market Report Introduction
3 Chronic Gout Market Overview by Therapies
4 Methodology of Chronic Gout Epidemiology and Market
5 Executive Summary of Chronic Gout
6 Key Events
7 Disease Background and Overview: Chronic Gout
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Chronic Gout Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
